For this reason, it could be hypothesized that, also in dog, any modifications of the expression of CD13 and CD26 could be correlated with prostatic pathological conditions and represent a biomarker to be used as a diagnostic tool particularly for early and noninvasive diagnosis of BPH and prostatic neoplasia. This evidence concerns the gene DPP4 and benign prostatic hyperplasia.